Eli Lilly, Regeneron among first firms chosen for FDA's faster factory-review program
Eli Lilly and Regeneron are among the first seven companies selected for the US Food and Drug Administration's PreCheck Pilot Program, which aims to speed up reviews of new drug-manufacturing facilities. The initiative is designed to encourage more pharmaceutical production on US soil.
Eli Lilly and Regeneron are among the first seven companies the US Food and Drug Administration has selected for its PreCheck Pilot Program, CNBC has learned. The scheme is intended to speed up the review and approval of new drug-manufacturing facilities.
By shortening the time it takes to license new plants, the program aims to encourage companies to build production capacity inside the United States. Regulators argue that a more predictable inspection process will strengthen supply-chain resilience and reduce reliance on overseas manufacturing for critical medicines.
Analysts said the move was a positive signal for the US pharmaceutical sector, where incentives for domestic production have become a priority after recent supply disruptions and cost pressures. The FDA could expand the initiative depending on the results of the pilot, which involves a small group of established drugmakers.
Read next
Australian minister won't commit to delaying NDIS exit if supports aren't ready
The minister responsible for Australia's National Disability Insurance Scheme, Jenny McAllister, would not say whether the government will delay participants' exit from the scheme if foundational supports are not ready, but insisted the government will not leave people in freefall.
Luigi Mangione pleads guilty to killing UnitedHealthcare CEO
New commissioner takes on task of reforming culture at Australia's Defence Force
Singapore orders transshipping firms to declare true country of origin of goods
